Analyst Price Targets — SRPT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 3, 2026 8:44 pm | Ilya Zubkov | Loop Capital Markets | $25.00 | $15.87 | StreetInsider | Sarepta Therapeutics (SRPT) PT Raised to $25 at Freedom Capital Markets |
| March 3, 2026 5:00 pm | Andrew Tsai | Jefferies | $30.00 | $15.98 | StreetInsider | Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story" |
| January 27, 2026 12:18 pm | — | Robert W. Baird | $22.00 | $22.80 | TheFly | Sarepta price target raised to $22 from $15 at Baird |
| December 9, 2025 11:46 am | — | Wedbush | $32.00 | $21.86 | TheFly | Wedbush bullish on Sarepta, initiates with an Outperform |
| November 25, 2025 11:15 am | — | Bernstein | $20.00 | $18.91 | TheFly | Sarepta price target raised to $20 from $18 at Bernstein |
| November 5, 2025 10:28 am | — | Barclays | $20.00 | $16.20 | TheFly | Sarepta price target lowered to $20 from $22 at Barclays |
| November 5, 2025 9:33 am | Uy Ear | Mizuho Securities | $26.00 | $16.20 | StreetInsider | Mizuho Upgrades Sarepta Therapeutics (SRPT) to Outperform |
| November 4, 2025 10:13 am | Brian Skorney | Robert W. Baird | $15.00 | $24.45 | StreetInsider | Sarepta Therapeutics (SRPT) PT Lowered to $15 at Baird |
| October 30, 2025 11:13 am | Biren Amin | Piper Sandler | $16.00 | $23.45 | TheFly | Sarepta price target raised to $16 from $15 at Piper Sandler |
| September 9, 2025 1:26 pm | Joseph Schwartz | Leerink Partners | $15.00 | $17.57 | TheFly | Sarepta price target raised to $15 from $12 at Leerink |
Latest News for SRPT
Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2026-2027 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living…
AXQ Capital LP decreased its position in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 72.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,619 shares of the biotechnology company's stock after selling 39,088 shares during the quarter. AXQ
SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.
Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SRPT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.